AGENDA ITEM 1: FINANCE COMMITTEE MINUTES

Joint San Francisco Health Authority &
San Francisco Community Health Authority
Finance Committee Minutes
November 19, 2025
(11:00 am to 12:00 pm)

1. **Attendance.** In attendance were Steven Fugaro (Interim Chair), MD, Eddie Chan, Pharm.D. and Jian Zhang, DNP, MS, FNP-BC.

   Guests: Rianne Suico and Gordon Lam, from Baker Tilly, LLP (formerly Moss Adams)

2. **Welcome.** Dr. Fugaro, Interim Chair, opened the meeting and welcomed back Skip Bishop as Interim Chief Financial Officer, due to Anne Price's departure in late October. Dr. Fugaro welcomed Rianne Suico, and Gordon Lam, of Baker Tilly LLP, who will present the Annual Independent Audit Report.

3. **Review and Approval of Minutes from June 18, 2025**
   Motion to approve the Finance Committee minutes from June 18, 2025:
   Eddie Chan, PharmD
   Second: Jian Zhang, DNP, MS, FNP-BC
   The motion passed unanimously.

4. **Review and Approval of the Annual Independent Audit Report for FY 2024-25.**
   Skip Bishop, Interim CFO, introduced Rianne Suico, Partner, and Gordon Lam from Baker Tilly, LLP, the independent audit firm hired by San Francisco Health Plan (SFHP) (Moss Adams merged with Baker Tilly, LLP). The firm presented highlights from their FY 24-25 independent financial audit report. The auditors gave SFHP an "Unmodified Opinion," which is the highest opinion available (also known as a "clean opinion"). There were no significant or material comments in the document, "Communication to the Governing Board." There were no required or recommended adjustments to the journal entries. (A detailed audit report was provided in the Finance Committee packet.)

   The Finance Committee and audit consultants then met without SFHP staff. Upon returning, Dr. Fugaro shared that the auditors stated the audit went well.

   Dr. Fugaro thanked the auditors and SFHP management for another smooth audit.
   Motion to approve the Independent Audit Report for FY 2024-25:
   Eddie Chan, PharmD
   Second: Jian Zhang, DNP, MS, FNP-BC
   The motion passed unanimously.

5. **Review and Approval of Year-to-Date Unaudited Financial Statements and Investment Income Reports.** Mr. Bishop and Rand Takeuchi, Controller, reviewed the financial results and investment reports for the period ending September 30, 2025.

   Mr. Bishop and Mr. Takeuchi highlighted key metrics that demonstrated SFHP was in good financial condition, including a strong tangible net equity ratio.

Motion to approve the year-to-date unaudited financial and investment reports: Eddie Chan, PharmD
Second: Jian Zhang, DNP, MS, FNP-BC
The motion passed unanimously to forward to the full Governing Board for approval.

6. **Semi-Annual Program Integrity Report.** Nina Maruyama, Chief Officer, Compliance and Regulatory Affairs, provided an overview of the semi-annual program integrity report to the Finance Committee, which per the Governing Board by-laws, also serves as the Board's Regulatory Compliance and Oversight Committee. Among other highlights from the report, she reviewed the results of the annual staff training, investigation of potential fraud and abuse cases, and status of the implementation of the new fraud detection and case management software, which is on track for early 2026.

   Ms. Maruyama presented the new policy for the annual compliance training that is required of staff and Board members. The committee members stated that members of the Board that take the annual compliance training at their entities should be able to submit an attestation. Ms. Maruyama added that provision to the policy and the committee had no other issues with the policy.

7. **Adjourn.** Dr. Fugaro adjourned the meeting.